Validity of galactin-3 in acromegaly: comparison with traditional markers

Saadi, Maryam Thaer; Mohammed, Noor Ulhuda G.; Abed, Baydaa Ahmed; Farhan, Layla Othman; Salman, Isam Noori

doi:10.1007/s11845-024-03674-w

Ir J Med Sci

2024

DOI: 10.1007/s11845-024-03674-w

|View full text |Cite

Validity of galactin-3 in acromegaly: comparison with traditional markers

Maryam Thaer Saadi,

Noor Ulhuda G. Mohammed,

Baydaa Ahmed Abed

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Serum visfatin in patients with type two diabetic retinopathy

Salman,

Mohammed,

Atta

et al. 2024

Diabetes mellitus

View full text Add to dashboard Cite

BACKGROUND: The primary cause of blindness in diabetics is diabetic retinopathy (DR), the most common microvascular complication of diabetes, and visual impairment. Visfatin is an adipocytokine that aids in insulin activity during gestational diabetes and pregnancy.AIM: This study aimed to estimate serum visfatin levels in DR, proliferative (PDR), non-proliferative (NPDR), and healthy subjects (HS).MATERIALS AND METHODS: A 120-patient case-control study with a history of T2DM for more than 5 years as well as 30 healthy subjects enrolled in the study. Patients group divided into three sub-groups, DM, PDR, and NPDR. Visfatin levels were measured using a commercially available enzyme-linked immunosorbent assay kit. Triglyceride (TG), serum cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) levels and glycated haemoglobin (HbA1c) were assessed.RESULTS: The PDR patients and patients with poor glycemic control showed significantly increased visfatin levels compared with the HS group and T2DM patients without DR. The TC, TG, and DR group’s LDL-C levels were noticeably higher and significantly greater in PDR than in the group of HS.CONCLUSION: Visfatin levels have been linked to both the severity and existence of DR. and more in patients with poor glycemic control. Elevated lipids were associated with DR risk.

show abstract

Serum visfatin in patients with type two diabetic retinopathy

Salman,

Mohammed,

Atta

et al. 2024

Diabetes mellitus

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Validity of galactin-3 in acromegaly: comparison with traditional markers

Cited by 1 publication

References 24 publications

Serum visfatin in patients with type two diabetic retinopathy

Serum visfatin in patients with type two diabetic retinopathy

Contact Info

Product

Resources

About